India’s Dr. Reddy’s To Focus On Providing Niche Services
This article was originally published in PharmAsia News
Executive Summary
Dr. Reddy's Laboratories of India plans to change the way it does business, focusing on niche services to gain an edge in the highly competitive generic drugs business. As a lead-up to the new emphasis, the company has combined its custom pharmaceutical services with its division for active pharmaceutical ingredients. The new division is called Pharmaceutical Services and Active Ingredients. A senior vice president at Dr. Reddy's, Abhijit Mukerjee, is to head the new division, and says the move is intended to take advantage of "a huge wealth of expertise." His division plans to provide research and manufacturing services matched to its clients, many of the services involving chemical molecules. (Click here for more
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.